{"id":"insulin-lispro-biphasic-25","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This biphasic insulin combines 25% rapid-acting insulin lispro with 75% intermediate-acting insulin isophane (NPH), providing both immediate and sustained glucose control. Insulin lispro is a rapid-acting analog that binds to insulin receptors on muscle and adipose tissue, promoting glucose uptake and glycogen synthesis, while the NPH component provides basal coverage over several hours.","oneSentence":"Insulin Lispro Biphasic 25 is a premixed insulin formulation that rapidly lowers blood glucose by facilitating cellular glucose uptake and storage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:20.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT04023344","phase":"PHASE3","title":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":210},{"nctId":"NCT03606018","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-12","conditions":"Clamp Study","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin Lispro Biphasic 25","genericName":"Insulin Lispro Biphasic 25","companyName":"Geropharm","companyId":"geropharm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Lispro Biphasic 25 is a premixed insulin formulation that rapidly lowers blood glucose by facilitating cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}